4.7 Article

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update

Related references

Note: Only part of the references are listed.
Article Oncology

Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's Viewpoint

Daniel F. Hayes

Summary: Tumor biomarker tests (TBTs) are used to guide therapeutic strategies for cancer patients, but their clinical utility is not strictly defined. Considering various factors can lead to more objective conclusions and facilitate value-based decisions concerning the use of TBTs in patient care.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Article Oncology

Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2enegative advanced breast cancer: final overall survival results from SOLAR-1

F. Andre et al.

Summary: The study confirmed a certain efficacy in overall survival when alpelisib was added to fulvestrant treatment in patients with PIK3CA-mutated hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer, prolonging the median survival time.

ANNALS OF ONCOLOGY (2021)

Article Oncology

Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1

Eva Maria Ciruelos et al.

Summary: In the SOLAR-1 trial, treatment with alpelisib did not show a statistical difference in deterioration of Global Health Status/QoL between arms, while symptom subscales favored placebo for diarrhea, appetite loss, nausea or vomiting, and fatigue.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Article Oncology

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

Hope S. Rugo et al.

Summary: The study demonstrated that in patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer who progressed on treatment with CDK4/6 inhibitors plus aromatase inhibitors, the combination therapy of Alpelisib and Fulvestrant showed activity with manageable toxicity.

LANCET ONCOLOGY (2021)

Article Oncology

Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update

Beverly Moy et al.

Summary: This guideline provides recommendations on chemotherapy and targeted therapy for patients with HR-negative metastatic breast cancer, offering different treatment options based on patient's condition, such as combination chemotherapy, single-agent chemotherapy, or targeted therapy. Specific treatment options are also suggested for patients with different genetic mutations.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Article Oncology

FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer

Preeti Narayan et al.

Summary: The FDA granted regular approval to alpelisib in combination with fulvestrant for hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer patients. Results from the SOLAR-1 study showed a significant improvement in PFS with the combination therapy compared to the control group.

CLINICAL CANCER RESEARCH (2021)

Article Oncology

Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy

Mariya Rozenblit et al.

Summary: This study suggests that EE remains an effective treatment option after prior ET or ET + CDK4/6i use. Median TTNT of EE was longer for patients who received prior ET, whereas median OS was longer for patients who received prior ET + CDK4/6i. However, this improvement in OS was not statistically significant when indexed to the start of EE therapy suggesting that OS benefit is primarily driven by prior CDK4/6i use. EE remains an effective treatment option regardless of prior treatment option.

BREAST CANCER RESEARCH (2021)

Article Oncology

Management of Male Breast Cancer: ASCO Guideline

Michael J. Hassett et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Article Medicine, General & Internal

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

Dennis J. Slamon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Oncology

Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2-Advanced Breast Cancer

Veronique Dieras et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)

Article Oncology

Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2-Advanced Breast Cancer

Veronique Dieras et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)

Article Medicine, General & Internal

Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer

Fabrice Andre et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Article Medicine, General & Internal

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

S. -A. Im et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Article Immunology

The Impact of Unconscious Bias in Healthcare: How to Recognize and Mitigate It

Jasmine R. Marcelin et al.

JOURNAL OF INFECTIOUS DISEASES (2019)

Article Medicine, General & Internal

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

Jennifer K. Litton et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Article Medicine, General & Internal

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

N. C. Turner et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Article Oncology

Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline

Timothy Gilligan et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Article Oncology

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

Matthew P. Goetz et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Article Medicine, General & Internal

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

Mark Robson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Article Medical Informatics

Wilfully out of sight? A literature review on the effectiveness of cancer-related decision aids and implementation strategies

Anne Herrmann et al.

BMC MEDICAL INFORMATICS AND DECISION MAKING (2016)

Article Medicine, General & Internal

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

G. N. Hortobagyi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Article Medicine, General & Internal

Palbociclib and Letrozole in Advanced Breast Cancer

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Article Medicine, General & Internal

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer

Nicholas C. Turner et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Review Oncology

Are Cancer-Related Decision Aids Effective? A Systematic Review and Meta-Analysis

Mary Ann O'Brien et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

Editorial Material Oncology

Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers

Richard M. Simon et al.

JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)

Article Medicine, General & Internal

How quickly do systematic reviews go out of date? A survival analysis

Kaveh G. Shojania et al.

ANNALS OF INTERNAL MEDICINE (2007)